Dr. Umang Swami, MD
Claim this profileHuntsman Cancer Institute/University of Utah
Studies Prostate Cancer
Studies Thyroid Cancer
9 reported clinical trials
13 drugs studied
Area of expertise
1Prostate Cancer
Stage IV
Stage III
PTEN positive
2Thyroid Cancer
Stage IV
Affiliated Hospitals
Clinical Trials Umang Swami, MD is currently running
Radium-223 + Cabozantinib
for Kidney Cancer with Bone Metastasis
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Recruiting1 award Phase 216 criteria
Eribulin + Chemotherapy
for Bladder Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting2 awards Phase 3
More about Umang Swami, MD
Clinical Trial Related4 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Umang Swami, MD has experience with
- Cabozantinib
- XL092
- Enfortumab Vedotin
- Atezolizumab
- Cabozantinib S-malate
- Bortezomib
Breakdown of trials Umang Swami, MD has run
Prostate Cancer
Thyroid Cancer
Renal Cell Carcinoma
Medullary Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Umang Swami, MD specialize in?
Umang Swami, MD focuses on Prostate Cancer and Thyroid Cancer. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are Stage III.
Is Umang Swami, MD currently recruiting for clinical trials?
Yes, Umang Swami, MD is currently recruiting for 8 clinical trials in Salt Lake City Utah. If you're interested in participating, you should apply.
Are there any treatments that Umang Swami, MD has studied deeply?
Yes, Umang Swami, MD has studied treatments such as Cabozantinib, XL092, Enfortumab Vedotin.
What is the best way to schedule an appointment with Umang Swami, MD?
Apply for one of the trials that Umang Swami, MD is conducting.
What is the office address of Umang Swami, MD?
The office of Umang Swami, MD is located at: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah 84112 United States. This is the address for their practice at the Huntsman Cancer Institute/University of Utah.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.